Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 748,700 shares, a decrease of 33.7% from the February 13th total of 1,130,000 shares. Based on an average daily trading volume, of 56,200 shares, the days-to-cover ratio is currently 13.3 days. Approximately 3.5% of the shares of the stock are short sold.
Analysts Set New Price Targets
Several equities research analysts have commented on ACRV shares. Cantor Fitzgerald began coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.67.
Read Our Latest Report on Acrivon Therapeutics
Institutional Investors Weigh In On Acrivon Therapeutics
Acrivon Therapeutics Trading Up 7.3 %
NASDAQ ACRV opened at $5.44 on Monday. The stock’s 50-day moving average price is $5.62 and its two-hundred day moving average price is $6.80. The company has a market cap of $169.38 million, a PE ratio of -2.01 and a beta of 0.85. Acrivon Therapeutics has a 1 year low of $4.69 and a 1 year high of $11.90.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- Trading Halts Explained
- How to Build the Ultimate Everything ETF Portfolio
- The How and Why of Investing in Gold Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is an Earnings Surprise?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.